Trial Profile

Combinations of Sacituzumab Govitecan Plus Enfortumab Vedotin and Pembrolizumab for Metastatic Urothelial Carcinoma: the Double Antibody Drug Conjugate (DAD) and Double Antibody Drug Conjugate With Immunotherapy (DAD-IO) Phase I/II Trial

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary) ; Sacituzumab govitecan (Primary)
Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Adverse reactions; Therapeutic Use

04 Nov 2025 Planned End Date changed from 1 May 2026 to 1 May 2028.
04 Nov 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Feb 2027.
03 Jun 2025 The protocol has been amended to change in study phase with addition in treatment arm and some primary therapeutic endpoints.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com